nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ALB—Vismodegib—skin cancer	0.13	0.176	CbGbCtD
Naloxone—ALB—Vemurafenib—skin cancer	0.102	0.139	CbGbCtD
Naloxone—CYP2C8—Vismodegib—skin cancer	0.1	0.136	CbGbCtD
Naloxone—ABCB1—Vismodegib—skin cancer	0.0677	0.092	CbGbCtD
Naloxone—CYP3A4—Imiquimod—skin cancer	0.0586	0.0796	CbGbCtD
Naloxone—CYP3A4—Temozolomide—skin cancer	0.0586	0.0796	CbGbCtD
Naloxone—ALB—Fluorouracil—skin cancer	0.046	0.0625	CbGbCtD
Naloxone—CYP3A4—Vismodegib—skin cancer	0.0406	0.0551	CbGbCtD
Naloxone—ABCB1—Dactinomycin—skin cancer	0.0356	0.0484	CbGbCtD
Naloxone—CYP2C8—Fluorouracil—skin cancer	0.0355	0.0483	CbGbCtD
Naloxone—CYP3A4—Vemurafenib—skin cancer	0.0321	0.0436	CbGbCtD
Naloxone—ABCB1—Docetaxel—skin cancer	0.0184	0.025	CbGbCtD
Naloxone—CYP3A4—Docetaxel—skin cancer	0.011	0.015	CbGbCtD
Naloxone—CREB1—nerve—skin cancer	0.00603	0.132	CbGeAlD
Naloxone—CREB1—neck—skin cancer	0.00338	0.0739	CbGeAlD
Naloxone—OPRM1—nerve—skin cancer	0.00325	0.0709	CbGeAlD
Naloxone—CREB1—connective tissue—skin cancer	0.00243	0.053	CbGeAlD
Naloxone—CREB1—epithelium—skin cancer	0.0023	0.0503	CbGeAlD
Naloxone—TLR4—lymph node—skin cancer	0.00227	0.0496	CbGeAlD
Naloxone—CREB1—skin of body—skin cancer	0.00219	0.0478	CbGeAlD
Naloxone—CREB1—mammalian vulva—skin cancer	0.002	0.0436	CbGeAlD
Naloxone—Pulmonary oedema—Imiquimod—skin cancer	0.00187	0.0219	CcSEcCtD
Naloxone—ESR1—blood vessel—skin cancer	0.00186	0.0407	CbGeAlD
Naloxone—Encephalopathy—Fluorouracil—skin cancer	0.00181	0.0211	CcSEcCtD
Naloxone—CREB1—lymphoid tissue—skin cancer	0.00177	0.0387	CbGeAlD
Naloxone—CREB1—female reproductive system—skin cancer	0.00171	0.0374	CbGeAlD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00148	0.0172	CcSEcCtD
Naloxone—Irritability—Imiquimod—skin cancer	0.00146	0.017	CcSEcCtD
Naloxone—CREB1—head—skin cancer	0.00143	0.0312	CbGeAlD
Naloxone—Nervous system disorder—Vismodegib—skin cancer	0.0014	0.0163	CcSEcCtD
Naloxone—Skin disorder—Vismodegib—skin cancer	0.00138	0.0162	CcSEcCtD
Naloxone—ESR1—neck—skin cancer	0.00133	0.0291	CbGeAlD
Naloxone—OPRK1—female reproductive system—skin cancer	0.0013	0.0283	CbGeAlD
Naloxone—Gastrointestinal disorder—Vismodegib—skin cancer	0.00123	0.0144	CcSEcCtD
Naloxone—Pain—Vismodegib—skin cancer	0.00122	0.0142	CcSEcCtD
Naloxone—Depression—Imiquimod—skin cancer	0.00117	0.0137	CcSEcCtD
Naloxone—Cardiac disorder—Vemurafenib—skin cancer	0.00115	0.0134	CcSEcCtD
Naloxone—OPRD1—head—skin cancer	0.00113	0.0247	CbGeAlD
Naloxone—Abdominal pain—Vismodegib—skin cancer	0.00113	0.0132	CcSEcCtD
Naloxone—Angiopathy—Vemurafenib—skin cancer	0.00112	0.0131	CcSEcCtD
Naloxone—Mediastinal disorder—Vemurafenib—skin cancer	0.00112	0.013	CcSEcCtD
Naloxone—Chills—Vemurafenib—skin cancer	0.00111	0.013	CcSEcCtD
Naloxone—OPRK1—head—skin cancer	0.00108	0.0236	CbGeAlD
Naloxone—Coma—Fluorouracil—skin cancer	0.00106	0.0124	CcSEcCtD
Naloxone—Rhinorrhoea—Docetaxel—skin cancer	0.00104	0.0121	CcSEcCtD
Naloxone—Asthenia—Vismodegib—skin cancer	0.00102	0.0119	CcSEcCtD
Naloxone—CREB1—lymph node—skin cancer	0.001	0.0219	CbGeAlD
Naloxone—Flushing—Imiquimod—skin cancer	0.000981	0.0115	CcSEcCtD
Naloxone—Hot flush—Temozolomide—skin cancer	0.000979	0.0114	CcSEcCtD
Naloxone—Diarrhoea—Vismodegib—skin cancer	0.000975	0.0114	CcSEcCtD
Naloxone—Menopausal symptoms—Temozolomide—skin cancer	0.00097	0.0113	CcSEcCtD
Naloxone—Angiopathy—Imiquimod—skin cancer	0.000959	0.0112	CcSEcCtD
Naloxone—ESR1—connective tissue—skin cancer	0.000955	0.0208	CbGeAlD
Naloxone—Mediastinal disorder—Imiquimod—skin cancer	0.000953	0.0111	CcSEcCtD
Naloxone—Chills—Imiquimod—skin cancer	0.000948	0.0111	CcSEcCtD
Naloxone—Mental disorder—Imiquimod—skin cancer	0.000926	0.0108	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000912	0.0107	CcSEcCtD
Naloxone—ESR1—epithelium—skin cancer	0.000907	0.0198	CbGeAlD
Naloxone—Vomiting—Vismodegib—skin cancer	0.000906	0.0106	CcSEcCtD
Naloxone—Nervous system disorder—Vemurafenib—skin cancer	0.000864	0.0101	CcSEcCtD
Naloxone—Skin disorder—Vemurafenib—skin cancer	0.000855	0.00999	CcSEcCtD
Naloxone—Nausea—Vismodegib—skin cancer	0.000847	0.00989	CcSEcCtD
Naloxone—Agitation—Imiquimod—skin cancer	0.000846	0.00987	CcSEcCtD
Naloxone—Injection site reaction—Docetaxel—skin cancer	0.000834	0.00974	CcSEcCtD
Naloxone—Irritability—Fluorouracil—skin cancer	0.000805	0.0094	CcSEcCtD
Naloxone—Cardiac arrest—Fluorouracil—skin cancer	0.000802	0.00937	CcSEcCtD
Naloxone—Convulsion—Imiquimod—skin cancer	0.000797	0.00931	CcSEcCtD
Naloxone—Hypertension—Imiquimod—skin cancer	0.000794	0.00928	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000778	0.00908	CcSEcCtD
Naloxone—OPRM1—head—skin cancer	0.000771	0.0168	CbGeAlD
Naloxone—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00076	0.00888	CcSEcCtD
Naloxone—Nasopharyngitis—Fluorouracil—skin cancer	0.000754	0.00881	CcSEcCtD
Naloxone—Pulmonary oedema—Docetaxel—skin cancer	0.000747	0.00872	CcSEcCtD
Naloxone—Nervous system disorder—Imiquimod—skin cancer	0.000736	0.0086	CcSEcCtD
Naloxone—ABCB1—blood vessel—skin cancer	0.000736	0.0161	CbGeAlD
Naloxone—Tachycardia—Imiquimod—skin cancer	0.000733	0.00856	CcSEcCtD
Naloxone—Skin disorder—Imiquimod—skin cancer	0.000729	0.00852	CcSEcCtD
Naloxone—Hyperhidrosis—Imiquimod—skin cancer	0.000726	0.00848	CcSEcCtD
Naloxone—Depression—Temozolomide—skin cancer	0.000704	0.00821	CcSEcCtD
Naloxone—ESR1—lymphoid tissue—skin cancer	0.000698	0.0152	CbGeAlD
Naloxone—Flushing—Bleomycin—skin cancer	0.000697	0.00814	CcSEcCtD
Naloxone—Body temperature increased—Vemurafenib—skin cancer	0.000696	0.00813	CcSEcCtD
Naloxone—Paraesthesia—Imiquimod—skin cancer	0.000674	0.00787	CcSEcCtD
Naloxone—Chills—Bleomycin—skin cancer	0.000674	0.00787	CcSEcCtD
Naloxone—ESR1—female reproductive system—skin cancer	0.000674	0.0147	CbGeAlD
Naloxone—Dyspnoea—Imiquimod—skin cancer	0.000669	0.00782	CcSEcCtD
Naloxone—SLCO1A2—head—skin cancer	0.000663	0.0145	CbGeAlD
Naloxone—Hot flush—Docetaxel—skin cancer	0.000651	0.0076	CcSEcCtD
Naloxone—Flushing—Dactinomycin—skin cancer	0.00065	0.00759	CcSEcCtD
Naloxone—Gastrointestinal disorder—Imiquimod—skin cancer	0.000648	0.00757	CcSEcCtD
Naloxone—Menopausal symptoms—Docetaxel—skin cancer	0.000645	0.00753	CcSEcCtD
Naloxone—Pain—Imiquimod—skin cancer	0.000642	0.0075	CcSEcCtD
Naloxone—Asthenia—Vemurafenib—skin cancer	0.000632	0.00738	CcSEcCtD
Naloxone—Hallucination—Temozolomide—skin cancer	0.00063	0.00736	CcSEcCtD
Naloxone—Chills—Dactinomycin—skin cancer	0.000628	0.00734	CcSEcCtD
Naloxone—Diarrhoea—Vemurafenib—skin cancer	0.000602	0.00703	CcSEcCtD
Naloxone—Abdominal pain—Imiquimod—skin cancer	0.000594	0.00693	CcSEcCtD
Naloxone—Body temperature increased—Imiquimod—skin cancer	0.000594	0.00693	CcSEcCtD
Naloxone—Cardiac disorder—Temozolomide—skin cancer	0.000588	0.00686	CcSEcCtD
Naloxone—Flushing—Temozolomide—skin cancer	0.000588	0.00686	CcSEcCtD
Naloxone—Angiopathy—Temozolomide—skin cancer	0.000575	0.00671	CcSEcCtD
Naloxone—Mediastinal disorder—Temozolomide—skin cancer	0.000571	0.00667	CcSEcCtD
Naloxone—Chills—Temozolomide—skin cancer	0.000568	0.00664	CcSEcCtD
Naloxone—ESR1—head—skin cancer	0.000563	0.0123	CbGeAlD
Naloxone—Vomiting—Vemurafenib—skin cancer	0.00056	0.00654	CcSEcCtD
Naloxone—Mental disorder—Temozolomide—skin cancer	0.000555	0.00648	CcSEcCtD
Naloxone—CYP2C8—female reproductive system—skin cancer	0.000555	0.0121	CbGeAlD
Naloxone—Nasopharyngitis—Docetaxel—skin cancer	0.000544	0.00636	CcSEcCtD
Naloxone—Asthenia—Imiquimod—skin cancer	0.000539	0.00629	CcSEcCtD
Naloxone—Nausea—Vemurafenib—skin cancer	0.000523	0.00611	CcSEcCtD
Naloxone—Tremor—Temozolomide—skin cancer	0.000517	0.00603	CcSEcCtD
Naloxone—Diarrhoea—Imiquimod—skin cancer	0.000514	0.006	CcSEcCtD
Naloxone—Agitation—Temozolomide—skin cancer	0.000507	0.00592	CcSEcCtD
Naloxone—Paraesthesia—Bleomycin—skin cancer	0.000479	0.00559	CcSEcCtD
Naloxone—Convulsion—Temozolomide—skin cancer	0.000478	0.00558	CcSEcCtD
Naloxone—Vomiting—Imiquimod—skin cancer	0.000477	0.00557	CcSEcCtD
Naloxone—Hypertension—Temozolomide—skin cancer	0.000476	0.00556	CcSEcCtD
Naloxone—Dyspnoea—Bleomycin—skin cancer	0.000476	0.00555	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000466	0.00544	CcSEcCtD
Naloxone—ALB—lymph node—skin cancer	0.000462	0.0101	CbGeAlD
Naloxone—Pain—Bleomycin—skin cancer	0.000456	0.00533	CcSEcCtD
Naloxone—Nausea—Imiquimod—skin cancer	0.000446	0.00521	CcSEcCtD
Naloxone—Nervous system disorder—Temozolomide—skin cancer	0.000441	0.00515	CcSEcCtD
Naloxone—Convulsion—Fluorouracil—skin cancer	0.00044	0.00514	CcSEcCtD
Naloxone—Skin disorder—Temozolomide—skin cancer	0.000437	0.0051	CcSEcCtD
Naloxone—Hyperhidrosis—Temozolomide—skin cancer	0.000435	0.00508	CcSEcCtD
Naloxone—Pain—Dactinomycin—skin cancer	0.000425	0.00497	CcSEcCtD
Naloxone—Body temperature increased—Bleomycin—skin cancer	0.000422	0.00492	CcSEcCtD
Naloxone—Nervous system disorder—Fluorouracil—skin cancer	0.000407	0.00475	CcSEcCtD
Naloxone—Tachycardia—Fluorouracil—skin cancer	0.000405	0.00473	CcSEcCtD
Naloxone—Paraesthesia—Temozolomide—skin cancer	0.000404	0.00472	CcSEcCtD
Naloxone—Dyspnoea—Temozolomide—skin cancer	0.000401	0.00468	CcSEcCtD
Naloxone—ESR1—lymph node—skin cancer	0.000394	0.0086	CbGeAlD
Naloxone—Abdominal pain—Dactinomycin—skin cancer	0.000393	0.00459	CcSEcCtD
Naloxone—Body temperature increased—Dactinomycin—skin cancer	0.000393	0.00459	CcSEcCtD
Naloxone—Flushing—Docetaxel—skin cancer	0.000391	0.00456	CcSEcCtD
Naloxone—Cardiac disorder—Docetaxel—skin cancer	0.000391	0.00456	CcSEcCtD
Naloxone—Gastrointestinal disorder—Temozolomide—skin cancer	0.000389	0.00454	CcSEcCtD
Naloxone—Pain—Temozolomide—skin cancer	0.000385	0.00449	CcSEcCtD
Naloxone—Asthenia—Bleomycin—skin cancer	0.000383	0.00447	CcSEcCtD
Naloxone—Angiopathy—Docetaxel—skin cancer	0.000382	0.00446	CcSEcCtD
Naloxone—Mediastinal disorder—Docetaxel—skin cancer	0.00038	0.00443	CcSEcCtD
Naloxone—Chills—Docetaxel—skin cancer	0.000378	0.00441	CcSEcCtD
Naloxone—CYP3A4—female reproductive system—skin cancer	0.000376	0.0082	CbGeAlD
Naloxone—Paraesthesia—Fluorouracil—skin cancer	0.000372	0.00435	CcSEcCtD
Naloxone—Dyspnoea—Fluorouracil—skin cancer	0.00037	0.00432	CcSEcCtD
Naloxone—Mental disorder—Docetaxel—skin cancer	0.000369	0.00431	CcSEcCtD
Naloxone—ABCB1—epithelium—skin cancer	0.000358	0.00782	CbGeAlD
Naloxone—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000358	0.00418	CcSEcCtD
Naloxone—Asthenia—Dactinomycin—skin cancer	0.000357	0.00417	CcSEcCtD
Naloxone—Body temperature increased—Temozolomide—skin cancer	0.000356	0.00415	CcSEcCtD
Naloxone—Abdominal pain—Temozolomide—skin cancer	0.000356	0.00415	CcSEcCtD
Naloxone—Pain—Fluorouracil—skin cancer	0.000355	0.00414	CcSEcCtD
Naloxone—Diarrhoea—Dactinomycin—skin cancer	0.00034	0.00397	CcSEcCtD
Naloxone—Vomiting—Bleomycin—skin cancer	0.000339	0.00396	CcSEcCtD
Naloxone—Body temperature increased—Fluorouracil—skin cancer	0.000328	0.00383	CcSEcCtD
Naloxone—Asthenia—Temozolomide—skin cancer	0.000323	0.00377	CcSEcCtD
Naloxone—Convulsion—Docetaxel—skin cancer	0.000318	0.00371	CcSEcCtD
Naloxone—Nausea—Bleomycin—skin cancer	0.000317	0.0037	CcSEcCtD
Naloxone—Hypertension—Docetaxel—skin cancer	0.000317	0.0037	CcSEcCtD
Naloxone—Vomiting—Dactinomycin—skin cancer	0.000316	0.00369	CcSEcCtD
Naloxone—ABCB1—mammalian vulva—skin cancer	0.000311	0.00678	CbGeAlD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00031	0.00362	CcSEcCtD
Naloxone—Diarrhoea—Temozolomide—skin cancer	0.000308	0.0036	CcSEcCtD
Naloxone—Nausea—Dactinomycin—skin cancer	0.000296	0.00345	CcSEcCtD
Naloxone—Nervous system disorder—Docetaxel—skin cancer	0.000293	0.00343	CcSEcCtD
Naloxone—Tachycardia—Docetaxel—skin cancer	0.000292	0.00341	CcSEcCtD
Naloxone—Skin disorder—Docetaxel—skin cancer	0.000291	0.00339	CcSEcCtD
Naloxone—Vomiting—Temozolomide—skin cancer	0.000286	0.00334	CcSEcCtD
Naloxone—Diarrhoea—Fluorouracil—skin cancer	0.000284	0.00331	CcSEcCtD
Naloxone—ABCB1—lymphoid tissue—skin cancer	0.000276	0.00602	CbGeAlD
Naloxone—Paraesthesia—Docetaxel—skin cancer	0.000269	0.00314	CcSEcCtD
Naloxone—Nausea—Temozolomide—skin cancer	0.000267	0.00312	CcSEcCtD
Naloxone—Dyspnoea—Docetaxel—skin cancer	0.000267	0.00312	CcSEcCtD
Naloxone—ABCB1—female reproductive system—skin cancer	0.000266	0.00581	CbGeAlD
Naloxone—Vomiting—Fluorouracil—skin cancer	0.000264	0.00308	CcSEcCtD
Naloxone—Gastrointestinal disorder—Docetaxel—skin cancer	0.000258	0.00302	CcSEcCtD
Naloxone—Pain—Docetaxel—skin cancer	0.000256	0.00299	CcSEcCtD
Naloxone—Nausea—Fluorouracil—skin cancer	0.000246	0.00288	CcSEcCtD
Naloxone—Body temperature increased—Docetaxel—skin cancer	0.000237	0.00276	CcSEcCtD
Naloxone—Abdominal pain—Docetaxel—skin cancer	0.000237	0.00276	CcSEcCtD
Naloxone—ABCB1—head—skin cancer	0.000222	0.00485	CbGeAlD
Naloxone—Asthenia—Docetaxel—skin cancer	0.000215	0.00251	CcSEcCtD
Naloxone—Diarrhoea—Docetaxel—skin cancer	0.000205	0.00239	CcSEcCtD
Naloxone—Vomiting—Docetaxel—skin cancer	0.00019	0.00222	CcSEcCtD
Naloxone—Nausea—Docetaxel—skin cancer	0.000178	0.00208	CcSEcCtD
Naloxone—ABCB1—lymph node—skin cancer	0.000156	0.0034	CbGeAlD
Naloxone—OPRD1—Signaling by GPCR—PTGER4—skin cancer	9.51e-05	0.000717	CbGpPWpGaD
Naloxone—CREB1—Signaling by SCF-KIT—IL6—skin cancer	9.5e-05	0.000716	CbGpPWpGaD
Naloxone—CREB1—Toll-Like Receptors Cascades—IL6—skin cancer	9.5e-05	0.000716	CbGpPWpGaD
Naloxone—CREB1—Downstream signaling of activated FGFR—HRAS—skin cancer	9.49e-05	0.000716	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	9.35e-05	0.000705	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB4—HRAS—skin cancer	9.34e-05	0.000705	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—HRAS—skin cancer	9.21e-05	0.000695	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—PTGER4—skin cancer	9.18e-05	0.000693	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	9.16e-05	0.000691	CbGpPWpGaD
Naloxone—CREB1—Downstream signaling of activated FGFR—IL6—skin cancer	9.09e-05	0.000685	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—SHH—skin cancer	9.03e-05	0.000681	CbGpPWpGaD
Naloxone—CREB1—B Cell Activation—KRAS—skin cancer	9.01e-05	0.000679	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—GLI2—skin cancer	8.98e-05	0.000678	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	8.96e-05	0.000676	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—GLI2—skin cancer	8.95e-05	0.000675	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—CDK4—skin cancer	8.94e-05	0.000675	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB4—IL6—skin cancer	8.94e-05	0.000675	CbGpPWpGaD
Naloxone—CREB1—Downstream signal transduction—HRAS—skin cancer	8.92e-05	0.000673	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR—HRAS—skin cancer	8.88e-05	0.00067	CbGpPWpGaD
Naloxone—CREB1—EGF/EGFR Signaling Pathway—HRAS—skin cancer	8.88e-05	0.00067	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB2—HRAS—skin cancer	8.83e-05	0.000667	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—IL6—skin cancer	8.81e-05	0.000665	CbGpPWpGaD
Naloxone—CREB1—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	8.8e-05	0.000664	CbGpPWpGaD
Naloxone—CREB1—DAP12 signaling—HRAS—skin cancer	8.79e-05	0.000663	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—IL6—skin cancer	8.76e-05	0.000661	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTCH2—skin cancer	8.75e-05	0.00066	CbGpPWpGaD
Naloxone—CREB1—Disease—SHH—skin cancer	8.72e-05	0.000658	CbGpPWpGaD
Naloxone—CREB1—Disease—ENO2—skin cancer	8.72e-05	0.000658	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CSPG4—skin cancer	8.69e-05	0.000656	CbGpPWpGaD
Naloxone—CREB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	8.66e-05	0.000654	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	8.62e-05	0.00065	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MC1R—skin cancer	8.57e-05	0.000646	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PTCH1—skin cancer	8.56e-05	0.000646	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—SMO—skin cancer	8.56e-05	0.000646	CbGpPWpGaD
Naloxone—CREB1—Downstream signal transduction—IL6—skin cancer	8.54e-05	0.000644	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MC1R—skin cancer	8.54e-05	0.000644	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR—IL6—skin cancer	8.5e-05	0.000641	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—IL6—skin cancer	8.47e-05	0.000639	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB2—IL6—skin cancer	8.46e-05	0.000638	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—GLI1—skin cancer	8.44e-05	0.000637	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—GLI1—skin cancer	8.42e-05	0.000635	CbGpPWpGaD
Naloxone—CREB1—DAP12 signaling—IL6—skin cancer	8.41e-05	0.000635	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—NRAS—skin cancer	8.36e-05	0.000631	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PTGER4—skin cancer	8.34e-05	0.000629	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	8.33e-05	0.000628	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—HRAS—skin cancer	8.27e-05	0.000624	CbGpPWpGaD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	8.27e-05	0.000624	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR in disease—HRAS—skin cancer	8.27e-05	0.000624	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR—HRAS—skin cancer	8.2e-05	0.000618	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	8.14e-05	0.000614	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR in Cancer—HRAS—skin cancer	8.12e-05	0.000613	CbGpPWpGaD
Naloxone—CREB1—Signaling by PDGF—HRAS—skin cancer	8.09e-05	0.00061	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SUFU—skin cancer	8e-05	0.000604	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SUFU—skin cancer	7.98e-05	0.000602	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR in disease—IL6—skin cancer	7.92e-05	0.000597	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—IL6—skin cancer	7.92e-05	0.000597	CbGpPWpGaD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	7.92e-05	0.000597	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—GLI2—skin cancer	7.85e-05	0.000592	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR—IL6—skin cancer	7.85e-05	0.000592	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—TP53—skin cancer	7.81e-05	0.000589	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR in Cancer—IL6—skin cancer	7.78e-05	0.000587	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTCH2—skin cancer	7.76e-05	0.000586	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—PTGER4—skin cancer	7.76e-05	0.000585	CbGpPWpGaD
Naloxone—CREB1—Signaling by PDGF—IL6—skin cancer	7.74e-05	0.000584	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—NRAS—skin cancer	7.7e-05	0.000581	CbGpPWpGaD
Naloxone—CREB1—Immune System—FOXO4—skin cancer	7.7e-05	0.000581	CbGpPWpGaD
Naloxone—CREB1—B Cell Activation—HRAS—skin cancer	7.65e-05	0.000578	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—SHH—skin cancer	7.63e-05	0.000576	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—TP53—skin cancer	7.53e-05	0.000568	CbGpPWpGaD
Naloxone—CREB1—Transmission across Chemical Synapses—HRAS—skin cancer	7.5e-05	0.000566	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MC1R—skin cancer	7.49e-05	0.000565	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—GLI1—skin cancer	7.38e-05	0.000557	CbGpPWpGaD
Naloxone—TLR4—Immune System—NRAS—skin cancer	7.33e-05	0.000553	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	7.33e-05	0.000553	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—KRAS—skin cancer	7.24e-05	0.000546	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—SMO—skin cancer	7.24e-05	0.000546	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PTCH1—skin cancer	7.24e-05	0.000546	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—KRAS—skin cancer	7.2e-05	0.000543	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—IL6—skin cancer	7.15e-05	0.000539	CbGpPWpGaD
Naloxone—CREB1—Disease—FOXO4—skin cancer	7.11e-05	0.000536	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	7.08e-05	0.000534	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PTGER4—skin cancer	7.04e-05	0.000532	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	7.01e-05	0.000529	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SUFU—skin cancer	7e-05	0.000528	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—NRAS—skin cancer	6.97e-05	0.000526	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—IL6—skin cancer	6.89e-05	0.00052	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	6.78e-05	0.000511	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—GLI2—skin cancer	6.63e-05	0.000501	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	6.63e-05	0.0005	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—KRAS—skin cancer	6.63e-05	0.0005	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—TP53—skin cancer	6.43e-05	0.000485	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MC1R—skin cancer	6.33e-05	0.000477	CbGpPWpGaD
Naloxone—TLR4—Immune System—KRAS—skin cancer	6.31e-05	0.000476	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—GLI1—skin cancer	6.24e-05	0.000471	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—HRAS—skin cancer	6.12e-05	0.000462	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SHH—skin cancer	6.1e-05	0.000461	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SHH—skin cancer	6.08e-05	0.000459	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RASA1—skin cancer	6.07e-05	0.000458	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RASA1—skin cancer	6.05e-05	0.000456	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—KRAS—skin cancer	6e-05	0.000453	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	6e-05	0.000452	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SUFU—skin cancer	5.91e-05	0.000446	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ENO2—skin cancer	5.91e-05	0.000446	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GLI2—skin cancer	5.88e-05	0.000444	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—IL6—skin cancer	5.86e-05	0.000442	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTCH1—skin cancer	5.79e-05	0.000437	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SMO—skin cancer	5.79e-05	0.000437	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTCH1—skin cancer	5.77e-05	0.000435	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SMO—skin cancer	5.77e-05	0.000435	CbGpPWpGaD
Naloxone—CREB1—Neuronal System—HRAS—skin cancer	5.75e-05	0.000434	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—HRAS—skin cancer	5.63e-05	0.000425	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTGER4—skin cancer	5.63e-05	0.000425	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTGER4—skin cancer	5.62e-05	0.000424	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MC1R—skin cancer	5.61e-05	0.000423	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GLI1—skin cancer	5.53e-05	0.000417	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—IL6—skin cancer	5.48e-05	0.000413	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—IL6—skin cancer	5.39e-05	0.000407	CbGpPWpGaD
Naloxone—TLR4—Immune System—HRAS—skin cancer	5.36e-05	0.000405	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SHH—skin cancer	5.34e-05	0.000403	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.33e-05	0.000402	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RASA1—skin cancer	5.3e-05	0.0004	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PLIN2—skin cancer	5.3e-05	0.0004	CbGpPWpGaD
Naloxone—ALB—Metabolism—PLIN2—skin cancer	5.27e-05	0.000398	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SUFU—skin cancer	5.24e-05	0.000396	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL6—skin cancer	5.13e-05	0.000387	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—HRAS—skin cancer	5.1e-05	0.000385	CbGpPWpGaD
Naloxone—CREB1—Disease—ERCC2—skin cancer	5.06e-05	0.000382	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTCH1—skin cancer	5.06e-05	0.000382	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SMO—skin cancer	5.06e-05	0.000382	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—FOXO4—skin cancer	4.98e-05	0.000375	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—NRAS—skin cancer	4.97e-05	0.000375	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—FOXO4—skin cancer	4.96e-05	0.000374	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTGER4—skin cancer	4.92e-05	0.000372	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—IL6—skin cancer	4.88e-05	0.000368	CbGpPWpGaD
Naloxone—CREB1—Disease—TERT—skin cancer	4.75e-05	0.000358	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	4.74e-05	0.000357	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.62e-05	0.000349	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PLIN2—skin cancer	4.62e-05	0.000348	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SHH—skin cancer	4.51e-05	0.00034	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RASA1—skin cancer	4.48e-05	0.000338	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—NRAS—skin cancer	4.39e-05	0.000331	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—FOXO4—skin cancer	4.35e-05	0.000328	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—KRAS—skin cancer	4.28e-05	0.000323	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTCH1—skin cancer	4.27e-05	0.000323	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SMO—skin cancer	4.27e-05	0.000323	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CSPG4—skin cancer	4.27e-05	0.000322	CbGpPWpGaD
Naloxone—ALB—Metabolism—CSPG4—skin cancer	4.25e-05	0.00032	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—NRAS—skin cancer	4.22e-05	0.000318	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTGER4—skin cancer	4.16e-05	0.000314	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SHH—skin cancer	4e-05	0.000302	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RASA1—skin cancer	3.97e-05	0.0003	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SMO—skin cancer	3.79e-05	0.000286	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTCH1—skin cancer	3.79e-05	0.000286	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—KRAS—skin cancer	3.78e-05	0.000285	CbGpPWpGaD
Naloxone—CREB1—Disease—BRAF—skin cancer	3.76e-05	0.000284	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CSPG4—skin cancer	3.72e-05	0.000281	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTGER4—skin cancer	3.69e-05	0.000278	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FOXO4—skin cancer	3.68e-05	0.000277	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—HRAS—skin cancer	3.64e-05	0.000275	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—KRAS—skin cancer	3.63e-05	0.000274	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—ERCC2—skin cancer	3.57e-05	0.000269	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—IL6—skin cancer	3.48e-05	0.000263	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ERCC2—skin cancer	3.43e-05	0.000259	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TERT—skin cancer	3.32e-05	0.000251	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TERT—skin cancer	3.31e-05	0.00025	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FOXO4—skin cancer	3.26e-05	0.000246	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—HRAS—skin cancer	3.21e-05	0.000242	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.17e-05	0.000239	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HRAS—skin cancer	3.09e-05	0.000233	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—IL6—skin cancer	3.08e-05	0.000232	CbGpPWpGaD
Naloxone—CREB1—Disease—PTGS2—skin cancer	3.04e-05	0.000229	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TERT—skin cancer	2.91e-05	0.000219	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ENO2—skin cancer	2.9e-05	0.000219	CbGpPWpGaD
Naloxone—ALB—Metabolism—ENO2—skin cancer	2.89e-05	0.000218	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PLIN2—skin cancer	2.84e-05	0.000215	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.82e-05	0.000213	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—NRAS—skin cancer	2.8e-05	0.000211	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—NRAS—skin cancer	2.79e-05	0.000211	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—BRAF—skin cancer	2.63e-05	0.000199	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—BRAF—skin cancer	2.62e-05	0.000198	CbGpPWpGaD
Naloxone—CREB1—Immune System—NRAS—skin cancer	2.56e-05	0.000193	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ENO2—skin cancer	2.53e-05	0.000191	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TERT—skin cancer	2.46e-05	0.000185	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—NRAS—skin cancer	2.45e-05	0.000185	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—KRAS—skin cancer	2.41e-05	0.000182	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—KRAS—skin cancer	2.4e-05	0.000181	CbGpPWpGaD
Naloxone—CREB1—Disease—NRAS—skin cancer	2.36e-05	0.000178	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—BRAF—skin cancer	2.3e-05	0.000174	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CSPG4—skin cancer	2.29e-05	0.000173	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.27e-05	0.000171	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.26e-05	0.00017	CbGpPWpGaD
Naloxone—CREB1—Immune System—KRAS—skin cancer	2.2e-05	0.000166	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TERT—skin cancer	2.18e-05	0.000164	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—KRAS—skin cancer	2.11e-05	0.000159	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—NRAS—skin cancer	2.07e-05	0.000156	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—skin cancer	2.06e-05	0.000155	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HRAS—skin cancer	2.05e-05	0.000155	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HRAS—skin cancer	2.04e-05	0.000154	CbGpPWpGaD
Naloxone—CREB1—Disease—KRAS—skin cancer	2.03e-05	0.000153	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—skin cancer	1.96e-05	0.000148	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—skin cancer	1.95e-05	0.000147	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—BRAF—skin cancer	1.94e-05	0.000147	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NRAS—skin cancer	1.93e-05	0.000146	CbGpPWpGaD
Naloxone—CREB1—Immune System—HRAS—skin cancer	1.87e-05	0.000141	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—skin cancer	1.79e-05	0.000135	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HRAS—skin cancer	1.79e-05	0.000135	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—skin cancer	1.78e-05	0.000134	CbGpPWpGaD
Naloxone—CREB1—Disease—HRAS—skin cancer	1.73e-05	0.00013	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—BRAF—skin cancer	1.72e-05	0.00013	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—skin cancer	1.71e-05	0.000129	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ERCC2—skin cancer	1.69e-05	0.000127	CbGpPWpGaD
Naloxone—ALB—Metabolism—ERCC2—skin cancer	1.68e-05	0.000127	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—skin cancer	1.66e-05	0.000125	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NRAS—skin cancer	1.65e-05	0.000125	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—skin cancer	1.65e-05	0.000125	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NRAS—skin cancer	1.65e-05	0.000124	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ENO2—skin cancer	1.56e-05	0.000118	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HRAS—skin cancer	1.51e-05	0.000114	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—skin cancer	1.48e-05	0.000111	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ERCC2—skin cancer	1.47e-05	0.000111	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—skin cancer	1.45e-05	0.000109	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NRAS—skin cancer	1.45e-05	0.000109	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—skin cancer	1.42e-05	0.000107	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—skin cancer	1.42e-05	0.000107	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HRAS—skin cancer	1.41e-05	0.000107	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—skin cancer	1.27e-05	9.55e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—skin cancer	1.26e-05	9.52e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—skin cancer	1.24e-05	9.39e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NRAS—skin cancer	1.22e-05	9.22e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HRAS—skin cancer	1.21e-05	9.13e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HRAS—skin cancer	1.21e-05	9.1e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—skin cancer	1.16e-05	8.74e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—skin cancer	1.15e-05	8.71e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—skin cancer	1.11e-05	8.34e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NRAS—skin cancer	1.08e-05	8.17e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HRAS—skin cancer	1.06e-05	7.98e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—skin cancer	1.05e-05	7.94e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—skin cancer	1.01e-05	7.64e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—skin cancer	1.01e-05	7.63e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—skin cancer	1.01e-05	7.59e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—skin cancer	9.35e-06	7.05e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—skin cancer	9.33e-06	7.04e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ERCC2—skin cancer	9.05e-06	6.83e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HRAS—skin cancer	8.94e-06	6.74e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—skin cancer	8.81e-06	6.65e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—skin cancer	8.56e-06	6.46e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—skin cancer	8.29e-06	6.25e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HRAS—skin cancer	7.93e-06	5.98e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—skin cancer	7.59e-06	5.72e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—skin cancer	5.43e-06	4.1e-05	CbGpPWpGaD
